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ABSTRACT 
The ocular drug delivery deviates through a number of anatomical and physiological barriers, which have been a bottleneck for the 
ophthalmologists. The ocular barriers, static and dynamic, decrease the absorption of the therapeutic agents and the entry of the xenobiotics. Thus, 
a conventional ocular dosage form has various disadvantages of its use in ocular diseases. Hence, an ideal ocular delivery system has always been 
aimed, where the bioavailability of a drug is maintained for a longer period of time. The present review aims to focus on the drawbacks of the 
conventional ocular therapy and the advantages of designing novel delivery systems, with their certain specific advantages in ocular 
pharmacokinetics and the enhancement of bioavailability. These novel approaches emphasize on the benefits of various ocular drug delivery 
systems, like eye ointments, gels and use of viscosity enhancers, prodrugs, penetration enhancers, microparticles, liposomes, niosomes, ocular 
inserts, implants, intravitreal injections, nanoparticles, nanosuspension, microemulsion, dendrimers, in situ gels, iontophoresis and periocular 
injections. The compiled data presented in this review will act as a good information resource and reference point for further researches in the field 
of ocular drug delivery aiming non-invasive sustained release of drugs in the anterior and posterior segments of the eye.  
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INTRODUCTION 
Human eye is a complex structure, both anatomically and 
physiologically, that makes it a unique organ consisting of its 
physiologically independent functions. Its wide range of varied 
structures also challenges to develop drug delivery systems for it. 
The major problem in the conventional ocular drug delivery system 
with eye drops is their fast and extensive elimination from the eye, 
causing extensive loss of the drug [1, 2]. In eye drops, only a small 
portion of a drug penetrates through the corneal layer and arrives in 
the internal tissues present in the eye [3, 4]. Broad classification of 
ocular drug delivery results in two types, those concerned with the 
anterior and posterior segments. For vision-threatening ocular 
diseases, conventional drug delivery systems, such as eye drops, 
suspensions and ointments, cannot be used for optimal treatment 
[5]. About 90% of the ophthalmic formulations in the market are 
available in the form of eye drops and the sites of action are diseases 
occurring in the anterior segment of the eye [6]. Topical delivery of 
drugs through conventional approaches is unable to make it reach 
the posterior segment of the eye. Formulations like eye drops and 
ointments, when instilled into the cul-de-sac, are wiped away from 
eye region quickly because of the flow of tear and lachrymal nasal 
drainage. Most of the drug is drained away and only a small portion 
reaches the site of action; so, it needs frequent dosing to achieve a 
therapeutic effect. The eye’s posterior segment includes the retina, 
vitreous humour and choroid; the diseases occurring in these 
regions can be cured by using intravenous and intravitreal drug 
delivery systems, implants or by administering drug through 
periocular route and needs high concentration of the drug as well. 
For ophthalmic drug delivery, the posterior segment of eye is 
frequently a choice of interest to locate drugs using novel 
approaches [7]. The rationale behind this review and novelty of this 
study are to highlight the newer developments in the 
pharmaceutical ophthalmic formulations, such as formulation of in 
situ gels, nanoparticles, liposomes, nanosuspension, microemulsion, 
ocular inserts and so on, and their progress to overcome the 
problems associated with the existing conventional dosage forms 
and also to improve the bioavailability as well as the sustained 
release of the drug at the target location [8].  
Barriers for ocular drug delivery  
Ocular drug delivery suffers from the following barrier effects:  
Drug loss from the ocular surface  
After using the dosage form of the drug in the ocular system, flow of 
lacrimal fluid wipes out a portion of the drug from its surface and its 
turnout rate is only about 1 μl/min, whereas, a major portion of the 
drug is wiped out through the nasolacrimal duct quickly within 
minutes. Other sources of drug removal include the systemic 
absorption of the drug, instead of being absorbed through the ocular 
route. Systemic absorption is mostly directed through the 
conjunctival sac to the local blood capillaries or takes place after the 
solution flows to the nasal cavity [9]. 
Lacrimal fluid-eye barriers  
Absorption of the drug from the lacrimal fluid can be limited by the 
corneal epithelium present in the eye. Tight junctions formed from 
corneal epithelial cells limit the permeation of the drug 
paracellularly. Lipophilic drugs show higher permeability in the 
cornea as compared to hydrophilic drugs. In other terms, we can say 
that conjunctiva has leaky epithelium compared to that of the cornea 
and also has twenty times greater surface area than the cornea that 
supports rapid systemic absorption. 
Blood-ocular barriers  
Blood-ocular barriers are present in the bloodstream, which protect 
the eye from xenobiotics. It comprises of two parts, namely blood-
aqueous barrier and blood-retina barrier. The anterior blood-eye 
barrier is composed of endothelial cells in the uvea, i.e., the middle 
layer of the eye below sclera, iris, ciliary body and choroid. This 
barrier works to prevent the entry of hydrophilic drugs present in 
plasma to the aqueous humor and also limits the entrance of plasma 
albumin in aqueous humor. The posterior barrier which resides in 
between the eye and stream of plasma consists of retinal pigment 
epithelium (RPE) and retinal capillaries, resulting in tight wall 
junction. Choroid vasculature comprises of extensive blood flow and 
leaky walls, due to which easy access of drugs occurs in the 
choroidal extravascular space, but again their distribution in the 
retina is limited due to the presence of RPE and retinal endothelium 
[10]. 
Advantages of ocular drug delivery systems  
The advantages of ocular drug delivery systems have been 
summarized below:  
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 They impart accuracy and uniformity in dosing rate. Pulsed 
dosing of conventional systems can be avoided. 
 Sustained and controlled release of drugs can be achieved.  
 By increasing corneal contact time, they cause enhancement in 
the ocular bioavailability of drugs and it is achieved by effective 
adherence of the drug to the corneal surface.  
 For the prevention of loss of ocular tissues, targeting within the 
ocular globe is to be done. 
 They bypass the protective ophthalmic barriers, such as 
drainage, lacrimation and conjunctival absorption.  
 They also improve patient’s compliance, offer comfort and 
enhance therapeutic drug performance. 
 They provide better housing of delivery systems.  
 The make self-administration of drugs possible.  
 Systemic and visual side effects are lower and absorption is 
faster [11]. 
Disadvantages of ophthalmic drug delivery systems 
The major drawbacks of ophthalmic drug delivery systems are as 
follows:  
 Short contact time of drug solution and eye surface. 
 Poor bioavailability.  
 Instability for dissolved drugs.  
 Use of preservatives [12]. 
Limitations of ocular drug delivery  
Ocular delivery of drugs suffers from the following limitations:  
 Termination of the dosage form is not possible during an 
emergency.  
 Interference with vision.  
 Faces difficulty in placement and removal of the dosage form.  
 During sleep or while rubbing eyes, there may be an occasional 
loss of the drug [12]. 
Routes of ocular drug delivery  
The various possible routes for ocular drug delivery are described 
below:  
Intravitreal route  
In this route, the medication is delivered through injections in the 
vitreous humor of the eye. This route of administration is used to 
cure a number of eye disorders; the delivery through this ocular 
route is shown in fig. 1. 
Intracameral route  
Anterior or posterior chambers of the eye are the sites of action for a 
drug in this route of administration. It can be demonstrated by 
injecting an anesthetic agent into the anterior chamber of the eye, 
usually during surgery. 
Perilocular route  
The drug is administered around the eye in this route of 
administration. It can be explained by peril ocular steroid injection 
involving the placement of steroids around the eye to treat 
intraocular inflammation or swelling [13]. 
Suprachoroidal route  
Supra choroid region of the eye is the target in this route of 
administration. The space existing between the sclera and the 
choroid is termed as suprachoroidal space. 
Subconjunctival route  
In this route, the drug is administered to the mucus membrane, 
comprising of the open space of the eyeball and the inner surface of 
the eyelids. 
Topical route  
Eye drops are the best examples of ophthalmic dosage forms used 
for topical administration of drugs in the eye as compared to 
ointments, gels and emulsions, which are used to cure the diseases 
of the anterior segment of the eye. It is the most convenient method 
drug delivery to eye, due to ease of administration and lower cost. 
Systemic route  
Common barriers to the systemic delivery of ophthalmic drugs are 
blood-aqueous barrier and blood-retinal barrier (BRB) for the 
anterior segment and posterior segments of eye, respectively [14]. 
 
 
Fig. 1: Routes of ocular drug delivery [14] 
 
Challenges in ophthalmic drug delivery systems 
Challenges in ocular drug delivery systems are to design a 
therapeutic system which can provide an optimal concentration of a 
drug at the target region and with high therapeutic efficacy. Rapid 
absorption of drugs occurs due to the corneal anatomy, physiology 
and barrier functions, so quick instillations of eye drops are 
mandatory to balance the therapeutic level in tear film or at targeted 
sites. Side effects of using frequent dosing of drug solution are that it 
can induce toxicity at the ocular surface and cause cellular damage 
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as well. Most of ocular dosage forms are poor in bioavailability, due 
to the precorneal loss, including solution drainage, lacrimation, tears 
dynamics, tear dilution, conjunctival absorption, nonproductive 
absorption, the transient residence time in the cul-de-sac and tear 
turnover. Other challenges include relative impermeability of 
corneal epithelial membrane, causing problems in delivering drugs 
at the anterior segment following topical administration. 
Approximately 1% or even less of the instilled dose of the drug 
reaches the intraocular tissues due to various anatomical and 
physiological hurdles, which reduces the absorption of a drug. For 
better clinical results, topical dosage form needs to maintain a 
balance between the lipophilicity and hydrophilicity along with 
higher contact time [15]. 
The challenges in ocular drug delivery systems are categorized as 
follows:  
Anterior segment delivery challenges  
Topical formulations are mostly preferred over systemic 
formulations in the ocular delivery system because if any drug 
formulation is administered to eye, before reaching the 
anatomical barrier of the cornea, the drug molecule has to face 
the precorneal barriers, the tear film and conjunctiva, which 
come first in the pathway and slow the penetration of the active 
moiety in the eye. Precorneal loss factors are responsible for 
poor bioavailability of the drugs in most of the ocular 
formulations, as shown in fig. 2. 
 
 
Fig. 2: Precorneal factors influencing bioavailability of topically applied ophthalmic drugs [15] 
 
Moreover, frequent instillations of eye drops are necessary to 
maintain a therapeutic drug level in the tear film or at the site of 
action, but the frequent use of highly concentrated drug solutions 
may induce toxic side effects and cellular damage at the ocular 
surface. 
Posterior segment delivery challenges  
BRB inhibits the entry of topically applied ocular drugs at the 
posterior segment of eye. Delivery of drugs is inhibited by some 
factors at the posterior segment of ocular tissue and this effect is 
also responsible for poor ocular bioavailability. The BRB is 
responsible for limiting the effect of the intravenous route at the 
posterior site for drug delivery [16] and it also limits the entry of the 
systemically administered drug in the retina [17]. For curing 
diseases in the posterior segment of the eye, there is a need for high 
concentration of vitreal drugs. BRB is permeable to more lipophilic 
molecules and so allows the entry of such drugs in the posterior 
segment of the eye. Frequent administration and high concentration 
of drug cause side effects systematically [18]. A major challenge to 
deliver drugs to the posterior segment of the eye is to maintain the 
therapeutic concentration of the drugs, for a longer period of time 
and minimizing the number of injections as well. Elimination of drug 
through the anterior route follows to the aqueous humor and, 
finally, outflows to the humor in the anterior chamber. Many drugs 
are eliminated through the posterior route, crossing a path of the 
blood-retinal barrier to the systemic circulation (fig. 3). 
 
 
Fig. 3: Fate of ophthalmic drug delivery system [15] 
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Approaches in ophthalmic drug delivery systems 
A number of approaches have been used in the early stages for 
better results. These approaches, categorized into two types, are:  
 Bioavailability improvement and 
 Controlled release drug delivery 
The first type aims to maximize corneal drug absorption and minimize 
precorneal drug loss using viscosity and penetration enhancers, 
prodrugs, gels and liposomes. The second one is for the delivery of 
active ophthalmic moiety in the form of a sustained delivery system by 
providing controlled and continuous delivery like implants, inserts, 
nanoparticles, micro particulates, and colloids. There are a number of 
traditional approaches, such as viscosity enhancers, gel, penetration 
enhancer, prodrug and liposomes which enhance the bioavailability, 
while the newer developments, i.e., ocuserts, nanosuspension, 
nanoparticles, liposomes, niosomes and implants improve both 
bioavailability and release of drugs in a controlled manner in the 
anterior segment of the eye. In the posterior segment of the eye, drug 
reaches through intravitreal injections, iontophoresis, subconjunctival 
injection and periocular routes [19, 20]. 
Approaches to improve ocular bioavailability 
Use of viscosity enhancers  
Viscosity-increasing polymers are highly preferred additive in the 
ophthalmic formulations due to their properties of enhancing viscosity 
and thereby imparting benefit to the penetration of the drug into the 
anterior chamber of the eye by lowering the elimination rate from the 
preocular area, resulting in increase in precorneal residence time and 
transcorneal penetration, but having very fewer effects for enhancing 
bioavailability in human beings. Examples of polymers are polyvinyl 
alcohol (PVA), polyvinylpyrrolidone (PVP), methylcellulose, 
hydroxylethylcellulose, hydroxylpropyl methylcellulose (HPMC) and 
hydroxypropyl cellulose [21]. As per Saettone et al. (1984), in their 
study of tropicamide solution, by using PVA, HPMC, and PVP solution, 
at concentrations yielding the same viscosity of 20 cst, PVA has been 
reported to be the most effective among all, probably due to the 
adhesive property of PVA and its capability to enhance the thickness of 
the precorneal tear film [21]. Saettone et al. (1982) have stated in their 
study that the retention of drug in the precorneal tear film does not 
strictly belong to vehicle viscosity, but also with surface spreading 
properties of the vehicle and to the capability of a polymer to use 
water as the vehicle spreads over the ocular surface with each eye 
blinking [22].  
Gel formulation  
Gels are known to be significantly dilute cross-linked systems, which 
show rigidity in the steady-state. Gels are generally liquid, but behave 
like solids due to their three-dimensional cross-linked structure within 
the liquid [23-25]. On the other side, if the gels have extremely high 
viscosity, they cannot improve bioavailability; instead, they will 
control the release, which leads to reduced frequency of dosing to once 
a day. The highly viscous solution even leads to blurred vision and 
matted eyelids, which substantially decrease patient’s compliance. In 
aqueous gel, viscosity building agents, such as PVA, polyacrylamide, 
poloxamer, HPMC, Carbomer, polymethylvinylether, Maleic anhydride, 
and hydroxylpropylethylcellulose are incorporated, whereas hydrogel 
or swellable water-insoluble polymers give rise to controlled drug 
delivery systems [26]. 
Prodrug formulation  
By the development of prodrugs, many properties of the formulation 
can be improved, which make it suitable for increasing drug 
permeability through the cornea. It includes modification of the 
chemical structure that imparts new characteristics to the active 
moiety i.e. site-specificity and selectivity [27]. This can be explained 
through examples; the formulations which have been developed as 
prodrugs, are epinephrine, phenylephrine, timolol, and Pilocarpine. 
Other prodrugs are dipiverine, diester of pivalic acid and 
epinephrine showing seventeen fold more permeability via cornea 
as compared to that of epinephrine, which is caused by its six 
hundred folds more lipophilicity at pH 7.2. So a minor dose of the 
drug solution (dipiverine), spreads over the entire eyeball and has a 
therapeutic effect exactly the same as of epinephrine. When 
compared with conventional eye drops consist of 2% epinephrine, 
eye drops of dipiverine 0.1% show only mild activity by lowering the 
intraocular pressure with a significant reduction of side effects [28]. 
Penetration enhancers  
Corneal epithelial membrane plays an important role in terms of 
permeability. So, by increasing its permeability, the transport 
property around cornea can be enhanced [29, 30]. Agents showing 
such properties are chelating agents, preservatives (like 
benzalkonium chloride), surfactants and bile acid salts, but due to 
local toxicity, they cannot be used in development ophthalmic 
formulation [31, 32]. 
Liposomes  
Liposomes are defined as microscopic vesicles which consist of one or 
more concentric lipid bilayers, divided via water or aqueous buffer 
compartments. Liposomes are widely used in ocular formulations due to 
their property of having intimate contact with eye surfaces, mainly 
corneal and conjunctival area, thus drug absorption through ocular route 
can be increased [33]. Formulation of liposomes can be developed by 
using phosphatidylcholine, stearylamine and various amounts of 
cholesterol or lecithin and  -L-dipalmitoyl-phosphatidylcholine [34-37]. 
Major advantages of this type of delivery system are due to their 
properties, i.e., biocompatibility, biodegradability, amphiphilic property, 
relative toxicity [34, 35, 38]. Delivery of drug on targeted site or site-
specificity and release of drug in a sustained manner, are also its 
advantages. Liposomes are generally prepared for the drugs which have 
poor absorption, lower partition coefficient, poor solubility and having 
molecular weights in the range of medium to high [39]. Surface charge of 
liposomes is to be considered during the formulation of ocular delivery 
system; if liposomes are positively charged, they are observed to be 
preferably captured by negatively charged corneal surface, while the 
neutral or negatively charged liposomes are not captured by corneal 
surface. According to the number of researches reported, the active 
pharmaceutical ingredients being used in liposomal ophthalmic 
formulations are acyclovir, pilocarpine, acetazolamide, chloramphenicol 
and ciprofloxacin [36, 37]. 
Niosomes and discosomes  
Niosomes are chemically stable, bi-layered nanocarriers made up of 
nonionic surfactants and used as carriers for both hydrophilic and 
hydrophobic drugs. They do not have drawbacks like liposomes that 
are chemical instable, susceptible to oxidative degradation and made 
up of phospholipids that are very much unstable as well as 
expensive [34, 35, 40, 41]. Thus, niosomes have lots of advantages 
including that they are biodegradable, biocompatible and 
nonimmunogenic, which make them increase the contact time 
between drug and cornea, thereby increasing the bioavailability of 
drugs. A modified form of niosomes is discosomes that also acts as 
carrier for ophthalmic drugs. The size of discosomes lies between 12 
to 16 m. This gives it a benefit of not allowing it to enter in the 
general circulation and its disc shape provides better fit into the 
conjunctival sac [35]. The size of discosomes makes it different from 
niosomes, as the former consists of nonionic surfactants and 
SolulanC[24], a derivative of lanolin and a mixture of ethoxylated 
cholesterol (ether of cholesterol and polyethylene glycol) and 
ethoxylated fatty alcohols (ether of cetyl alcohol and polyethylene 
glycol). Use of niosomal carrier as a drug delivery system has been 
reported for genciclovir [42], cyclo-pentolate, or timolol [35]. 
Nanoparticles/nanospheres  
These are polymeric colloidal particles, size varying from 10 nm to 1 nm, 
where the drug is being dissolved, entrapped, encapsulated, or adsorbed 
[43]. It consists of a number of biodegradable substances, like natural or 
synthetic polymers, lipids, phospholipids and metals. To obtain 
nanoparticles, the drugs can be formulated in many ways as by 
integrating with the matrix or by attaching to the surface of 
biodegradable polymers used for the preparation. Nanoparticles used in 
delivering drug to ocular tissues are polylactides (PLAs), 
polycyanoacrylate, poly (D, L-lactides) and natural polymers such as 
chitosan, gelatine, sodium alginate and albumin. Approximately, since 
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last 10 y, nanoparticles have been used as carriers in delivering drug for 
ocular disorders and given promising results. A specific type of 
nanoparticles can be classified as small capsules having a central cavity 
surrounded by a polymeric membrane and solid matrix spheres, known 
as nanocapsules and nanospheres, respectively. Marchal et al. (1993) 
have reported that the nanocapsules exhibit better effect as compared to 
that of the nanospheres, because drug (betaxolol, carteolol) present in 
unionized form in the oily core, diffuses at a higher rate into the cornea 
[44]. A number of authors have reported that the nanocapsules are more 
efficient due to the presence of mucoadhesive property in it that shows a 
rise in the residence time and biological responses [45]. So, these can 
enhance the bioavailability of drugs at ocular site and also decrease the 
frequency of dosing. Alonso et al. (1995) have reported in their study 
that the nanoparticles made from poly-e-caprolactone having 
cyclosporine exhibit better corneal absorption with respect to the drug’s 
oily solution [46]. 
Nanosuspension and nanodispersions  
Nanosuspensions are generated for poorly water-soluble drugs 
suspended at nano size range in a suitable dispersion medium. This 
technology can be utilized in a good way for drug moiety that forms 
crystals with high energy content, due to which they are insoluble in 
organic (lipophilic) or hydrophilic media. Polymeric nanoparticle 
suspensions are being formulated using inert polymeric resins, 
which can be used as vital drug delivery vehicles, having the capacity 
to increase drug release as well as improve its bioavailability. The 
carriers having such type of properties can be used as inert carriers 
for ophthalmic drugs, because they donot cause any irritation to the 
cornea, iris or conjunctiva. An example of such carrier is polymeric 
nanoparticle suspension having flurbiprofen (FLU) as an active 
ingredient and eudragit RS 1001 and RL 1001 are polymers used. 
Nanodispersions of alginate chitosan produced for sustained drug 
delivery and improved transcorneal permeation have been reported 
by Morsi et al. (2015) [47, 48]. 
Microemulsion  
A stable dispersion of water in oil, facilitated by adding surfactant and 
co-surfactant in combination in a way to decrease interfacial tension, is 
termed as a microemulsion. Microemulsion leads to decrease in 
administration frequency and enhancing ocular drug bioavailability. 
Major advantages of this dosage form are its high thermodynamic 
stability, smaller droplet size, i.e., 100 nm (approx.) and clear 
appearance. Ansari et al. (2008) have reported a microemulsion 
formulation, which is an oil in water system consisting of pilocarpine as a 
drug, lecithin, propylene glycol, PEG 200 as surfactant/co-surfactants 
and isopropyl myristate forming the oil phase [49]. 
Dendrimers  
Dendrimers are symmetric structures made from repetitive 
branched molecules surrounding a central core, proposed recently 
as topical ocular drug delivery systems [50]. Frequently used 
dendrimers for delivery in ocular system are poly-(amidoamine) 
(PAMAM), PLL, polypropylenimines (PPI) and phosphorus 
dendrimers. These are used as carriers to deliver nucleic acid-based 
drugs, mostly in ocular delivery system [51], but sometimes used for 
drugs with low molecular weight that can be hydrophilic 
(antibiotics) or lipophilic (anti-glaucoma) drugs as well [52–58]. 
According to the reported methods, it has been found that the 
carrier’s performance can be increased by making a change on their 
surface using methods like PEGylation or acetylation, which also 
help in reducing their toxicity factors [53, 54, 59]. So, the advantages 
of using dendimers as carrier of drugs for topical applications are 
enhancement of the drug residence time in the pre-corneal area, 
increase in bioavailability of drugs and prolonged therapeutic effect 
[52, 55, 57, 58]. 
In situ forming gel 
Researchers have found the new concept of in situ gel in the 
early1980s. Delivery of drug to ocular system through in situ gel is 
mainly for enhancing viscosity to decrease drug drainage from the 
cornea. The pourable gels are in liquid form when applied, after 
which they undergo a phase transition, when reaches to cul-de-sac 
of eye and converted into a visco-elastic gel giving rise to a response 
to changes environmentally, thereby increasing the bioavailability of 
the drug automatically. The major disadvantages of the in situ gels 
are that they get affected by temperature, pH or ions. Bazzaz et al. 
(2018) reported that in situ gelling system provides better and 
prolonged effect of a drug rather than conventional eye drops [60]. 
Approaches for controlled and continuous ocular drug delivery 
The following ocular drug delivery systems have been reported for 
controlled as well as continuous release of drugs:  
Microparticles 
Microparticles are isotropic, transparent, translucent, 
thermodynamically stable system of oil, surfactant and water 
droplets the size of which ranges between 20 to 200 nm [61]. 
Microparticles are defined as micron-sized polymeric particles in 
which drugs in the polymeric matrices are suspended in liquid 
medium. Drugs are uniformly dispersed in the polymeric matrix or 
covalently bound to the backbone of the polymer [62]. During 
topical application in the eye these particles go into the ocular cul-
de-sac and the drug releases from it through a number of processes 
like diffusion, chemical reaction or polymer degradation. 
Microparticles increase precorneal residence time, which allow 
continuous and sustained release of the drug. Ultimately this leads 
to increased ocular bioavailability of the drug and minimizes 
frequency of dosing, but microparticulate preparations are generally 
not administered to the eye as they cause irritation due to their large 
particle size. Microparticles have properties like biodegradation, 
bio-adhesion, and biocompatibility, which make it suitable for 
fabrication with polymers. 
Ocular inserts 
Ophthalmic inserts are solid patches, which, when placed in the 
conjunctival sac of the eye, slow down the rate of drug release. 
Ocular inserts also overcome the problem of frequent dosing by 
maintaining drug concentration in an effective manner and give rise 
to controlled, sustained and continuous drug delivery. Ocular Inserts 
also have various advantages like enhanced drug absorption due to 
increased contact time and minimized dose and application 
frequency. The major disadvantages of these inserts are patient 
noncompliance with frequent feeling like the entry of foreign body 
in the eye, difficulty in self-insertion feels and feeling of loss of the 
insert from eye. Ocular inserts are made by various techniques that 
make them soluble, erodible and in hydrogel form [table 1] [63]. 
 
Table 1: Various types of ophthalmic inserts 
Types Description Reference(s) 
Erodible inserts The fabrication polymer is hydrophobic but biodegradable. The drug is released through the 
erosion of the surface of the insert. 
[64] 
Soluble inserts  
 
The fabrication polymer is hydrophilic and water-soluble. Drug is released by diffusion control for 
soluble drugs and dissolution for less soluble drugs. 
[65] 
Hydrophilic but water-
insoluble inserts  
The fabrication polymer is hydrophilic but water-insoluble. Drug is released by diffusion control for 
soluble drugs and dissolution for less soluble drugs.  
[64] 
Inserts using osmotic 
system 
 
A polymeric matrix in which the drug is dispersed as discrete small domains. Upon placement in the 
cul-de-sac, tears are imbibed into the matrix because of an osmotic pressure gradient created by 




The drug core is surrounded by a hydrophobic polymer membrane; this controls the diffusion of 
the drug from the core to the outside. 
[66] 
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Table 2: Marketed ophthalmic implants 
Registered name Active substance Mode of administration Reference(s) 
Vitrasert® Ganciclovir Surgical implantation at the pars plana [69] 
Retisert® Fluocinolone acetonide Surgical implantation at the pars plana [70] 
Medidur® Fluocinolone acetonide Injected in the vitreous cavity [70] 
Posurdex® Dexamethasone Injected or through a small incision at the pars plana [71] 
Surodex® Dexamethasone Placed underneath the scleral flap [70] 
 
Implants 
The aim of designing an intraocular implant is to prolong the activity 
of the drug, along with its controlled release by using a polymer or 
polymer system. An injectable delivery system of drug, like 
liposomes and nanoparticles, is easy to administer, but having 
limitation that after insertion, it becomes difficult to retract those 
particles during any complication, like toxic responses. So it is 
beneficial to use implants for balancing the rate and duration of drug 
release. Removal of ocular implants is easy and can be removed by 
surgical intervention. Implants can be categorized into two types 
based on the characteristics of the polymer(s) used:  
Nonbiodegradable implants 
They do not dissolve to any significant extent and are not even 
eroded in vivo [66]. 
Biodegradable implants 
They mostly dissolve in vivo with soluble components by processes 
such as enzymatic or nonenzymatic degradations [67, 68]. Examples 
of marketed implants used worldwide have been cited in table 2. 
Approaches for posterior segment drug delivery 
Intravitreal injections 
Research reports reveal that intravitreal injections for the posterior 
segment are gaining worldwide popularity as a drug delivery 
system, over the past few years. Injections are directly given into the 
posterior segment via pars plana for delivering drugs to overcome 
all barriers. A number of studies have been conducted to find out the 
pharmacokinetic parameters of antiviral agents, like ganciclovir 
[71], foscarnet [71] and cidofovir [72], antibiotics: Cefazolin [73], 
amikacin, moxifloxacin [74], ceftizoxime, ceftriaxone ceftazidime 
[75], clindamycin [76] and gentamicin [77], steroids: 
dexamethasone [78], triamcinolone acetonide [79] and monoclonal 
antibodies, such as rituximab [80], bevacizumab [80] following 
intravitreal injections. If the molecular weight of the drug is very 
high, vitreal retention times seem to be higher as well. Molecules 
that are larger, i.e., linear>40 kDa and globular molecules>70 kDa 
seem to have long retention time due to the presence of tight 
barriers around the vitreous humor [81, 82]. So, this route is 
preferable for higher molecular weight drugs (>500 Da) and also 
having longer half-lives. First-order rate kinetics is mainly 
responsible for the elimination of residues out of the vitreous 
humour [83]. Even the drug delivery through intravitreal injections 
can be gained by increasing concentrations of drugs in neural retina; 
side effects like retinal detachment due to repeated injections, 
retinal hemorrhage, endophthalmitis and other toxicities in the 
retina occurs because of more concentrations upon bolus dose 
administration that can cause patient’s non-compliance [84-87]. 
Ausayakhun et al. (2005), have found in their study, that the 
cytomegalovirus (CMV) retinitis can be controlled by using 
intravitreal ganciclovir (2 mg in 0.1 ml per) and the reported data 
has shown that 60% of the treated eyes have remained stable, 13% 
have shown improvement and 26% have shown a reduction in 
visual acuity [88]. However, a retinal detachment has been noticed 
in 6%, intravitreal hemorrhages observed in 1% and 
endophthalmitis observed in 1% of treated eyes. So we can observe 
from the study that the problems associated with intravitreal 
injections should be taken into consideration [88]. A number of 
other studies have also been carried out for similar findings, which 
have stated that the intravitreal injections are useful, but not good 
for posterior segment diseases [89-91]. Development in designing of 
drug delivery system and surgical procedures has led to the 
development of intravitreal implants that can be instilled inside the 
vitreous chamber for a longer duration. The difference between 
intravitreal injections and intravitreal implants is their 
administration time. Injections can be taken 2 or 3 times a week and 
preferably can be changed every month, respectively. 
Iontophoresis 
Ocular iontophoresis is one of the growing fields in research due to 
its noninvasive nature of delivering drugs to both the anterior and 
posterior segments of eye. Iontophoresis is defined as a noninvasive 
procedure for the transfer of ionized drugs via membranes with low 
electrical current [92, 93]. The drugs can move across the 
membranes by two ways, migration and electro-osmosis. Ocular 
iontophoresis, categorized as transcorneal, corneoscleral, or trans-
scleral [92], is considered as one of the most attractive options. 
OcuPhor™ system has been designed with the help of an applicator, 
dispersive electrode and a dose controller for trans scleral 
iontophoresis [94]. The device works, as it releases the active drug 
moiety into retina-choroid. Another similar device being made 
known by name called Visulex™, which allows specific transport of 
ionized molecules through the sclera. Antibiotics, which are 
successfully used, are gentamycin, tobramycin, and ciprofloxacin, 
but not vancomycin, due to its high molecular weight [95]. Fruitful 
results of delivery have been observed with drugs such as 
dexamethasone and antisense ODNs [96].  
Advantages 
 It can overcome the major side effects caused by intraocular 
injections and implants [97]. 
 Disease that might be cured using iontophoresis includes fungal 
keratitis, uveitis, retinitis, retinoblastoma, proliferative vitreal 
retinopathy and various retinal degenerations [98]. 
Disadvantages 
 As there is a chance of burns and pains because of excessive 
current density, it should be used in such a manner that it takes a 
short period for delivering the drug. 
 Drug should be in ionic form and have sufficient concentration 
because of high molecular weight, i.e., 8 000–12 000 [99]. 
Periocular route 
Periocular region is the region surrounding the eye. Among all the 
present routes, the periocular route is least painful and a promising 
route for delivery of the drug to the posterior segment of the eye. In 
drug delivery through periocular route, the drug is placed in the 
nearest position to sclera; as a result, vitreal drug levels can be 
noticed after 20-30 min. Periocular delivery includes retrobulbar, 
peribulbar, subtenon and subconjunctival routes. 
Retrobulbar injection 
Retrobulbar injection consists of drug solution deposition into 
retrobulbar space within the muscle cone. This route is used when 
the formulation needs to be in direct contact with the macular 
region. These injections are mostly given through specific 23 gauge 
sharp, 1.5-inch needle with a rounded tip and a 10 bend. 
Peribulbar injection 
Peribulbar injections are used for lowering the risk of injury to 
intraorbital structures related to retrobulbar administration during 
cataract surgery. The injection is given in the quadrant between the 
inferior and the lateral of the orbit using a 26-gauge half-inch 
disposable needle [100]. 
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Subtenon injection 
The Tenon’s capsule is a facial sheath of connective tissue sandwiched 
between the conjunctiva and episcleral plexus. The episcleral or 
subtenon’s space is a void space between the tenon’s capsule and sclera 
[101]. Subtenon injection is used to administer the drug in contact with 
sclera for prolonged periods because of its vascular nature. 
Subconjunctival injection 
The conjunctiva is a membrane that covers the sclera. The injection 
administered as a drug solution below the conjunctiva follows 
minimally invasive technique for delivering a drug to the posterior 
segment of the eye. About 500 μl of a drug solution as dosage form is 
injected into the subconjunctival area (bulbar conjunctiva) using a 
25/30 gauge, 30 mm long needle. Subconjunctival injection can be 
used in critical conditions in which a molecule diffuses directly 
through sclera [102]. 
Future prospects 
As challenges are more for eye as compared to the skin, so there is a 
need to focus more on non-invasive sustained drug release for eye 
disorders in both segments [103]. An ideal system is a system which 
should be able to administer an effective drug concentration at the 
targeted site for a prolonged period of time, while lowering systemic 
exposure. The output resulted from such systems, makes the system 
comfortable and easy to use. Patient’s compliance is one of the 
important factors for designing future ophthalmic drug delivery 
systems. Relevant strategies are being generated to overcome the 
drawbacks from each technology or by combining technologies. 
According to the reported studies, an ocular delivery system includes 
liposomes and nanoparticles in droppable gels and liposomes and 
nanoparticles coated with bioadhesive polymers. The challenges to be 
faced by topical ocular drug delivery systems in the future are:  
 The ocular route enhances bioavailability not more then 15 to 
20% of the administered dose. 
 Most of the marketed ocular formulations are highly non-
specific. So, it needs to focus on the development of new drug 
candidates initially intended for ocular use. 
 Further studies need to be carried out for exploring the non-
corneal routes, mainly for ionic/water-soluble contents and drug 
molecules with a preferential corneal absorption (and minimum 
absorption through nasal mucosa) should be explored. 
 Further researches are needed for suitable designing and 
packaging of the delivery systems. Several scientific and technological 
advancements need to progress in this field. Mainly the advancement 
in nanotechnology and biomaterials science may provide new 
technologies to improve the ophthalmic drug delivery systems. 
CONCLUSION 
Treatment of ocular diseases in an effective manner is a major 
challenge for scientists working in the field of ocular drug delivery 
because of nature of the ocular diseases, unique structure of the eye 
and barriers present in the system; particularly the posterior ocular 
segments make the system unapproachable. Many attempts have 
been made to enhance ocular bioavailability by manipulating 
product formulation using factors, such as viscosity and use of 
mucoadhesive polymers. These approaches have been found to be 
capable of increasing the corneal contact time and improving ocular 
bioavailability also. Therefore, it could be concluded that modern 
technology seems to be logically explored in various ways over the 
conventional approaches, examples of non-conventional approaches 
being the use of nanotechnology, microspheres, liposomes, 
appropriate prodrug in situ forming gel and iontophoresis as 
effective means of ocular drug delivery enhancing ocular absorption 
along with reduction in side effects. 
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